Skip to main content Skip to search Skip to main navigation

MHRA to pick up on-site inspections by end of March

The MHRA announces its return  to on-site risk based GxP inspections starting from 29 March 2021. However, it is planned to use a combined approach of both, remote and on-site inspections.

What has to be considered? 

  • The authority will pre-notifiy an on-site inspection within a minimum of 14 days in advance.

  • There will be a reasonable request for a minimized number of personnel on site, only. 

  • Social distancing will be given a top priority and a necessary remote standby of personnel will be discussed beforehand. 

  • Provision of documents via electronic means is preferred once on site, as well as in advance of physical linspection 

  • A physical inspection backroom is not expected but rather a workspace for inspectors allowing them social distancing. 

 

A detailed guidance for industry on the MHRA’s expectations is provided here.


Source:

 

MHRA: Update on MHRA UK risk-based GxP inspection programme 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
What should be considered in risk assessment?

What should be considered in risk assessment?

You can view the answer here:
Read more
 Basics on the Integrity of Container Closure Systems

Basics on the Integrity of Container Closure Systems

The integrity of a primary packaging system (container closure system) is essential to prevent product loss by leakage or evaporation and at the same time protect the product from contamination. The task of a primary packaging system (container closure system) is essentially to prevent the product from being lost (e.g. leakage, evaporation, etc.) and to prevent the product from being contaminated from the outside.

Read more
Previous
Next